1. Home
  2. GRC vs MESO Comparison

GRC vs MESO Comparison

Compare GRC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gorman-Rupp Company (The)

GRC

Gorman-Rupp Company (The)

N/A

Current Price

$77.78

Market Cap

2.1B

Sector

Industrials

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$16.66

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRC
MESO
Founded
1933
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
1994
2005

Fundamental Metrics

Financial Performance
Metric
GRC
MESO
Price
$77.78
$16.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
156.1K
176.4K
Earning Date
04-23-2026
02-26-2026
Dividend Yield
1.04%
N/A
EPS Growth
32.03
N/A
EPS
1.41
N/A
Revenue
$682,389,000.00
N/A
Revenue This Year
$6.62
$629.74
Revenue Next Year
$4.66
$30.65
P/E Ratio
$55.19
N/A
Revenue Growth
3.44
N/A
52 Week Low
$41.85
$12.66
52 Week High
$92.78
$21.50

Technical Indicators

Market Signals
Indicator
GRC
MESO
Relative Strength Index (RSI) 40.03 54.75
Support Level $75.97 $15.37
Resistance Level $79.02 $17.10
Average True Range (ATR) 2.59 0.37
MACD -0.51 0.09
Stochastic Oscillator 10.94 57.79

Price Performance

Historical Comparison
GRC
MESO

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: